Summit Therapeutics Stock Forecast, Price & News

Summit Therapeutics (NASDAQ:SMMT) Frequently Asked Questions

How has Summit Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Summit Therapeutics' stock was trading at $1.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SMMT stock has increased by 173.0% and is now trading at $5.16.
View which stocks have been most impacted by COVID-19.

Are investors shorting Summit Therapeutics?

Summit Therapeutics saw a decline in short interest during the month of October. As of October 29th, there was short interest totaling 420,300 shares, a decline of 22.3% from the October 14th total of 540,600 shares. Based on an average daily volume of 154,900 shares, the days-to-cover ratio is presently 2.7 days. Approximately 1.7% of the company's stock are short sold.
View Summit Therapeutics' Short Interest.

When is Summit Therapeutics' next earnings date?

Summit Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Summit Therapeutics.

How were Summit Therapeutics' earnings last quarter?

Summit Therapeutics Inc. (NASDAQ:SMMT) released its earnings results on Monday, November, 15th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.09. Summit Therapeutics had a negative trailing twelve-month return on equity of 96.34% and a negative net margin of 350.72%.
View Summit Therapeutics' earnings history.

Who are Summit Therapeutics' key executives?

Summit Therapeutics' management team includes the following people:

• Mr. Robert W. Duggan, Exec. Chairman & CEO (Age 77) (LinkedIn Profile)
• Mr. Michael Paul Donaldson, Chief Financial Officer (Age 44, Pay $296.2k)
• Dr. Mahkam Zanganeh M.B.A., D.D.S., MBA, COO & Director (Age 51, Pay $459.38k)
• Prof. Dame Kay Davies, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor (Age 71)
• Dr. David Jonathan Powell, Chief Scientific Officer (Age 51)
• Ms. Michelle Avery, Director of Investor Relations
• Mr. Dave Gancarz, Head of Investor Relations & Corp. Strategy
• Ms. Christine Armstrong, VP of Marketing?
• Mr. Campbell Hair, Head of HR?
• Dr. Jonathon Tinsley, Chief Scientific Officer of DMD (Age 62)

Who are some of Summit Therapeutics' key competitors?

Some companies that are related to Summit Therapeutics include Taro Pharmaceutical Industries (TARO), Agios Pharmaceuticals (AGIO), Dynavax Technologies (DVAX), Turning Point Therapeutics (TPTX), Trillium Therapeutics (TRIL), Avid Bioservices (CDMO), Global Blood Therapeutics (GBT), Erasca (ERAS), Enanta Pharmaceuticals (ENTA), Ironwood Pharmaceuticals (IRWD), Morphic (MORF), Atai Life Sciences (ATAI), Myovant Sciences (MYOV), Travere Therapeutics (TVTX) and IVERIC bio (ISEE).
View all of SMMT's competitors.

What other stocks do shareholders of Summit Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), (CATB), Gilead Sciences (GILD), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Total Return Fund (CRF), Ford Motor (F) and Martin Midstream Partners (MMLP).

When did Summit Therapeutics IPO?

(SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager.

What is Summit Therapeutics' stock symbol?

Summit Therapeutics trades on the NASDAQ under the ticker symbol "SMMT."

Who are Summit Therapeutics' major shareholders?

Summit Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Polar Capital Holdings Plc (6.57%), BlackRock Inc. (1.23%), Morgan Stanley (0.29%), Geode Capital Management LLC (0.26%), Russell Investments Group Ltd. (0.09%) and Bank of New York Mellon Corp (0.05%). Company insiders that own Summit Therapeutics stock include David Jonathan Powell, Maky Zanganeh and Robert W Duggan.
View institutional ownership trends for Summit Therapeutics.

Which institutional investors are selling Summit Therapeutics stock?

SMMT stock was sold by a variety of institutional investors in the last quarter, including Polar Capital Holdings Plc, California State Teachers Retirement System, Arrowstreet Capital Limited Partnership, Citadel Advisors LLC, and New York State Common Retirement Fund.
View insider buying and selling activity for Summit Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Summit Therapeutics stock?

SMMT stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Morgan Stanley, Geode Capital Management LLC, SG Americas Securities LLC, Inscription Capital LLC, Bank of New York Mellon Corp, and Advisor Group Holdings Inc.. Company insiders that have bought Summit Therapeutics stock in the last two years include Maky Zanganeh, and Robert W Duggan.
View insider buying and selling activity for Summit Therapeutics or or view top insider-buying stocks.

How do I buy shares of Summit Therapeutics?

Shares of SMMT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Summit Therapeutics' stock price today?

One share of SMMT stock can currently be purchased for approximately $5.16.

How much money does Summit Therapeutics make?

Summit Therapeutics has a market capitalization of $504.20 million and generates $20.17 million in revenue each year. The company earns $-52.70 million in net income (profit) each year or ($0.92) on an earnings per share basis.

How many employees does Summit Therapeutics have?

Summit Therapeutics employs 80 workers across the globe.

What is Summit Therapeutics' official website?

The official website for Summit Therapeutics is www.summitplc.com.

Where are Summit Therapeutics' headquarters?

Summit Therapeutics is headquartered at 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB.

How can I contact Summit Therapeutics?

Summit Therapeutics' mailing address is 136a Eastern Avenue Milton Park, Abingdon X0, OX144SB. The company can be reached via phone at 617-514-7149, via email at [email protected], or via fax at 44-12-3544-3999.